Allarity Therapeutics Stock Today
| ALLR Stock | USD 0.71 0.11 13.41% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Allarity Therapeutics is selling at 0.71 as of the 25th of February 2025; that is 13.41 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.68. Allarity Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts. The company has 1.41 M outstanding shares of which 489.06 K shares are presently shorted by private and institutional investors with about 0.3 trading days to cover. More on Allarity Therapeutics
Moving together with Allarity Stock
| 0.67 | A | Agilent Technologies Earnings Call Tomorrow | PairCorr |
Moving against Allarity Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Allarity Stock Highlights
| CEO, Founder | Thomas Jensen |
| Old Name | Allarity Therapeutics A/S |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Allarity Therapeutics (ALLR) is traded on NASDAQ Exchange in USA. It is located in 24 School Street, Boston, MA, United States, 02108 and employs 5 people. Allarity Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.06 M. Allarity Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.41 M outstanding shares of which 489.06 K shares are presently shorted by private and institutional investors with about 0.3 trading days to cover.
Allarity Therapeutics currently holds about 7.73 M in cash with (12.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Allarity Therapeutics Probability Of Bankruptcy
Ownership AllocationAllarity Therapeutics shows 12.3 percent of its outstanding shares held by insiders and 1.2 percent owned by other corporate entities.
Check Allarity Ownership Details
Allarity Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Allarity Therapeutics market risk premium is the additional return an investor will receive from holding Allarity Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | 0.3214 |
Allarity Stock Against Markets
Allarity Therapeutics Corporate Management
| Professor MD | CoFounder | Profile | |
| Joan Brown | Interim Reporting | Profile | |
| Alexander Epshinsky | Chief Officer | Profile | |
| James JD | Chief CEO | Profile | |
| Alexander CPA | Chief Officer | Profile | |
| Steen Knudsen | Founder Officer | Profile |
Already Invested in Allarity Therapeutics?
The danger of trading Allarity Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allarity Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allarity Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allarity Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.